Zura Bio Limited Class A Ordinary Shares (ZURA) Stock
Key stats
- Market cap
- $137.75M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$1.12
- Volume
- Loading
- 52-week high
- $7.44
- 52-week low
- $0.93
Source: third-party data provider, as of November 13, 2026
Compare with ZURA
Recent news

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURA

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
ZURA

Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURA

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 27.26
- MACD 12/26/9
- -0.58
- EMA 9 of MACD
- -0.31
- MACD histogram
- -0.26
- SMA 50
- $4.20
- Price below SMA 50
- EMA 50
- $4.01
- Price below EMA 50
- SMA 200
- $5.12
- Price below SMA 200
- EMA 200
- $4.77
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURA

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
ZURA

Zura Bio to Participate in the Cantor Global Healthcare Conference
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURA

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURA

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURA

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURA

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURA

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
ZURA

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
ZURA

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zura Bio Limited Class A Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sandeep Chidambar Kulkarni M.D. | Co-Founder, CEO & Director | 1981 |
| Ms. Kimberly Ann Davis J.D. | COO, Chief Legal Officer & Corporate Secretary | 1968 |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development | 1973 |
| Ms. Marlyn Mathew | VP of Finance & Accounting and Principal Financial & Accounting Officer | 1984 |
| Dr. Gary Whale Ph.D. | Chief Technology Officer | 1974 |
| Ms. Theresa Lowry | Chief Human Resources Officer | 1974 |
| Mr. Muzammil Mustufa | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 27.26
- MACD 12/26/9
- -0.58
- EMA 9 of MACD
- -0.31
- MACD histogram
- -0.26
- SMA 50
- $4.20
- Price below SMA 50
- EMA 50
- $4.01
- Price below EMA 50
- SMA 200
- $5.12
- Price below SMA 200
- EMA 200
- $4.77
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $7.67
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +106.1 | -52.0 | -3.9 | +31.2 | -14.2 | +0.0 | -5.4 | -28.9 | +3.2 | -2.3 | ||
| 2024 | -34.5 | +18.3 | -30.0 | +49.8 | +26.5 | -28.3 | +8.8 | +9.8 | -0.5 | +14.3 | -30.4 | -10.7 |
| 2025 | -20.0 | -20.9 | +10.3 | +29.4 | -31.3 | +4.0 | +33.3 | +36.0 | +114.4 | -5.0 | +4.3 | +40.9 |
| 2026 | +2.3 | +14.7 | -12.0 | -15.8 | -17.5 | +39.2 | +8.4 | +0.4 | -26.4 | -2.4 | -63.7 |



